Vorasidenib-VORANIGO is suitable for people and situations in which its use is not recommended

Vorasidenib (trade name VORANIGO) is an oral small molecule targeted drug, an IDH1/2 inhibitor, mainly used to treat glioma patients with IDH1 or IDH2 gene mutations. The drug selectively inhibits the activity of mutant isocitrate dehydrogenase (mutant IDH1/2) and blocks the abnormal accumulation of 2-hydroxyglutarate (2-HG), thereby restoring cellular metabolic balance and inhibiting tumor proliferation. The advent of vorsidenib provides a new option for precise targeted therapy for patients with IDH mutation-related gliomas.

The applicable population for Voxiranib mainly includes adult patients with low-grade gliomas whose IDH1 or IDH2 mutation is positive, especially those with residual or relapsed tumors after surgery. Clinical trials have shown that the drug can significantly delay tumor progression, improve imaging indicators, and have a positive impact on the survival and quality of life of some patients. In addition, for patients who cannot tolerate surgery or chemoradiotherapy, vorsidenib provides an oral targeted treatment option that reduces the risks of invasive treatments.

However, not all patients are candidates for vorsidenib. It is not recommended for use in the following situations: first, patients who are allergic to voxiranib or its excipients; second, pregnant or lactating women, as there is still a lack of sufficient safety data, which may cause potential risks to the fetus or infant; third, patients with severe liver and kidney damage, should use it with caution or adjust the dose under the guidance of a doctor; fourth, patients who use potent CYP3A inhibitors or inducers in combination need to assess the risk of drug interaction.

When using vorsidenib, patients should conduct genetic testing under the guidance of a professional doctor to confirm theIDH1/2 mutation status, and regularly monitor liver and kidney function, hematological indicators and imaging changes to ensure the efficacy and safety of the drug. At the same time, for patients who have received other targeted drugs or radiotherapy and chemotherapy in the past, disease progression and potential side effects should be comprehensively evaluated to formulate individualized treatment plans. Overall, vorsidenib provides a precise and relatively safe treatment option for patients with IDH mutated gliomas, but the indications and contraindications must be strictly followed to maximize benefit.

Reference link:https://www.drugs.com